secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0000950170-25-061439
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Q1 net loss $17.7M; pociredir 12mg cohort enrolled, 20mg cohort initiated
--------------------------------------------------------------------------------

- Net loss of $17.7M for Q1 2025 vs $26.9M in Q1 2024; cash $226.6M at March 31, 2025.
- Phase 1b PIONEER trial: enrollment complete for 12mg dose cohort (n=16), 20mg cohort started.
- On track to report 12mg cohort data in early Q3 2025 and 20mg cohort data by end of 2025.
- R&D expenses fell to $13.4M from $19.8M due to losmapimod discontinuation and Sanofi reimbursement.
- Cash runway expected to fund operations into at least 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000095017025061439/0000950170-25-061439-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000095017025061439/fulc-20250501.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-061439

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer